Evidence map›Paper›PMID 36573185›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2022

Physical activity and risk of all-cause mortality in patients with stable angina pectoris: Effect modification by β-blocker treatment.

Indu Dhar, Gard Ft Svingen, Eva Kr Pedersen, Arve Ulvik, Espen Ø Bjørnestad, Simon N Dankel, Gunnar Mellgren, Ottar K Nygård

Open access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Indu DharMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Gard Ft SvingenDepartment of Heart Disease, Haukeland University Hospital, Bergen, Norway.
Eva Kr PedersenDepartment of Heart Disease, Haukeland University Hospital, Bergen, Norway.
Arve UlvikBevital AS, Bergen, Norway.
Espen Ø BjørnestadDepartment of Cardiology, Stavanger University Hospital, Stavanger, Norway.
Simon N DankelMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Gunnar MellgrenMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Ottar K NygårdMohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NOBevital (Norway) · NOStavanger University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Physical activity (PA) influences sympathetic stimulation, platelet activation as well as vascular function, and has been associated with improved health outcomes in patients with coronary heart disease. β-blocker therapy reduces sympathetic activity and improves platelet and endothelial function. We investigated if β-blocker treatment modifies the association of self-reported PA with the risk of all-cause mortality. Methods: A total of 2284 patients undergoing elective coronary angiography for suspected stable angina pectoris (SAP) were studied. Using Cox modeling, we examined associations between PA (categorized as 'sedentary/inactive', 'low', 'moderate', and 'high') and all-cause mortality according to β-blocker therapy. Results: During a median follow-up of 10.3 years, 390 patients (17.1%) died. Higher PA was generally associated with a more favorable cardiovascular risk profile. Compared to the patients who were sedentary or inactive, the age and sex adjusted HRs (95% CI) for all-cause mortality were 0.89 (0.66-1.20), 0.73 (0.57-0.95) and 0.72 (0.55-0.95) in the low, moderate and high PA group, respectively. However, and notably, these risk estimates were 0.85 (0.60-1.20), 0.65 (0.47-0.89) and 0.58 (0.41-0.81) in β-blocker treated subjects vs. 1.00 (0.57-1.78), 0.96 (0.61-1.52) and 1.20 (0.74-1.95) in non-treated groups ( Conclusions: In patients with suspected SAP, increased PA was associated with reduced mortality risk primarily in patients treated with β-blockers.

Indexed as

MortalityPhysical activityStable angina pectorisβ-blocker therapy

Identifiers

PMID36573185
PMCPMC9789355
OpenAlexW4296196236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.